查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1468077

2024-2032 年糖尿病視網膜病變市場報告（按類型、治療類型、最終用戶（醫院和藥房、眼科診所、門診手術中心等）和地區）

Diabetic Retinopathy Market Report by Type, Treatment Type, End-User (Hospitals and Pharmacies, Eye Clinics, Ambulatory Surgical Centres, and Others), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 139 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年，全球糖尿病視網膜病變市場規模達81億美元。糖尿病盛行率激增、對有效治療的需求不斷成長以及人們對糖尿病視網膜病變早期診斷和治療的認知不斷提高，是推動市場發展的一些關鍵因素。

糖尿病視網膜病變 (DR) 是糖尿病的常見併發症，會影響視網膜，視網膜是眼睛中感知光線並向大腦發送訊號的部分。當高血糖損害視網膜中的小血管，導致其滲漏或阻塞時，就會發生這種情況。如果不及時治療，可能會導致視力喪失或失明。糖尿病視網膜病變主要有兩種類型，即非增殖性糖尿病視網膜病變和增殖性糖尿病視網膜病變。其診斷涉及全面的眼科檢查，其中可能包括螢光血管攝影和光學相干斷層掃描等測試。這些測試可以幫助確定 DR 的存在和嚴重程度，以便進行早期介入和治療。目前，DR 有多種治療方案，包括眼內類固醇注射、雷射治療和玻璃體切除術。眼內類固醇注射有助於減輕眼睛的發炎和腫脹，而雷射治療可用於密封滲漏的血管並防止視網膜進一步受損。在更嚴重的情況下，可能需要進行玻璃體切除術以去除眼睛中的血液或疤痕組織。

糖尿病視網膜病變市場趨勢：

全球糖尿病視網膜病變市場正在顯著成長，這主要是由於糖尿病盛行率上升和老年人口增加所致。同時，主要參與者正在積極致力於開發糖尿病視網膜病變的新治療解決方案，這正在促進市場成長。除此之外，抗VEGF藥物和緩釋植入物等新藥物和療法的開發也對市場成長做出了重大貢獻。此外，遠距醫療和人工智慧（AI）在糖尿病視網膜病變診斷和治療中的不斷採用正在推動市場成長。由於人們對糖尿病視網膜病變及其潛在後果的認知不斷增強，對有效治療的需求不斷成長，這是另一個生長誘導因素。此外，人們對糖尿病視網膜病變早期診斷和治療的認知不斷提高，加上眼科技術的進步，正在推動市場的成長。其他因素，例如醫療保健支出的增加、政府改善眼保健服務的各種舉措的實施以及有利的報銷政策的訂定，正在推動市場的成長。

本報告回答的關鍵問題：

  • 迄今為止，全球糖尿病視網膜病變市場表現如何，未來幾年將如何表現？
  • 全球糖尿病視網膜病變市場的促進因素、限制因素和機會是什麼？
  • 每個促進因素、限制因素和機會對全球糖尿病視網膜病變市場有何影響？
  • 主要區域市場有哪些？
  • 哪些國家代表了最具吸引力的糖尿病視網膜病變市場？
  • 依類型分類市場是怎麼樣的？
  • 糖尿病視網膜病變市場哪種類型最具吸引力？
  • 根據治療類型的市場分類是怎樣的？
  • 糖尿病視網膜病變市場中哪種治療類型最具吸引力？
  • 基於最終用戶的市場區隔是什麼？
  • 糖尿病視網膜病變市場中哪個是最具吸引力的最終使用者？
  • 全球糖尿病視網膜病變市場的競爭結構如何？
  • 全球糖尿病視網膜病變市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球糖尿病視網膜病變市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：按類型

  • 增殖性糖尿病視網膜病變
    • 市場走向
    • 市場預測
  • 非增殖性視網膜病變
    • 市場走向
    • 市場預測

第 7 章：市場區隔：依治療類型

  • 抗VEGF藥物
    • 市場走向
    • 市場預測
  • 類固醇植入物
    • 市場走向
    • 市場預測
  • 雷射手術
    • 市場走向
    • 市場預測
  • 玻璃體切除術
    • 市場走向
    • 市場預測

第 8 章：市場區隔：依最終用戶

  • 醫院和藥房
    • 市場走向
    • 市場預測
  • 眼科診所
    • 市場走向
    • 市場預測
  • 門診手術中心 (ASC)
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第13章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Alimera Sciences
    • Allergan Plc
    • Ampio Pharmaceuticals
    • Bayer Healthcare
    • BCN Peptides
    • Genentech
    • Kowa Group
    • Novartis AG
    • Regeneron Pharmaceuticals Inc.
    • Sirnaomics Inc.
Product Code: SR112024A1932

The global diabetic retinopathy market size reached US$ 8.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 13.0 Billion by 2032, exhibiting a growth rate (CAGR) of 5.2% during 2024-2032. The surging prevalence of diabetes, rising demand for effective treatments, and growing awareness regarding early diagnosis and treatment of diabetic retinopathy represent some of the key factors driving the market.

Diabetic retinopathy (DR) is a common complication of diabetes that affects the retina, the part of the eye that senses light and sends signals to the brain. It occurs when high blood sugar levels damage the small blood vessels in the retina, causing them to leak or become blocked. This can lead to vision loss or blindness if left untreated. There are two main types of diabetic retinopathy, namely non-proliferative diabetic retinopathy and proliferative diabetic retinopathy. Its diagnosis involves a comprehensive eye exam, which may include tests such as fluorescein angiography and optical coherence tomography. These tests can help to identify the presence and severity of DR, allowing for early intervention and treatment. Currently, there are several treatment options available for DR, including the use of intraocular steroid injections, laser treatment, and vitrectomy. Intraocular steroid injections can help to reduce inflammation and swelling in the eye, while laser treatment can be used to seal leaking blood vessels and prevent further damage to the retina. In more severe cases, a vitrectomy may be necessary to remove blood or scar tissue from the eye.

Diabetic Retinopathy Market Trends:

The global diabetic retinopathy market is witnessing significant growth, primarily driven by the rising prevalence of diabetes and the increasing geriatric population. In line with this, key players are actively working to develop new therapeutic solutions for diabetic retinopathy, which is bolstering market growth. Apart from this, the development of new drugs and therapies, such as anti-VEGF agents and sustained-release implants, has also significantly contributed to market growth. Additionally, the escalating adoption of telemedicine and artificial intelligence (AI) in the diagnosis and treatment of diabetic retinopathy is driving the market growth. The rising demand for effective treatments due to the growing awareness of diabetic retinopathy and its potential consequences is acting as another growth-inducing factor. Furthermore, the surging awareness regarding early diagnosis and treatment of diabetic retinopathy, coupled with advancements in ophthalmic technology, are fueling the market growth. Other factors, such as increasing healthcare expenditure, the implementation of various government initiatives to improve eye care services, and the availability of favorable reimbursement policies, are propelling the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global diabetic retinopathy market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, treatment type and end-user.

Type Insights:

Proliferative Diabetic Retinopathy

Non-proliferative Retinopathy

The report has provided a detailed breakup and analysis of the diabetic retinopathy market based on the type. This includes proliferative diabetic retinopathy and non-proliferative retinopathy. According to the report, the non-proliferative retinopathy segment dominates the market.

Treatment Type Insights:

Anti VEGF Drugs

Steroid Implants

Laser Surgeries

Vitrectomy

The report has provided a detailed breakup and analysis of the diabetic retinopathy market based on the treatment type. This includes anti VEGF drugs, steroid implants, laser surgeries, and vitrectomy. As per the report, the anti VEGF drugs segment holds the largest market share.

End-User Insights:

Hospitals and Pharmacies

Eye Clinics

Ambulatory Surgical Centres (ASCs)

Others

The report has provided a detailed breakup and analysis of the diabetic retinopathy market based on the end-user. This includes hospitals and pharmacies, eye clinics, ambulatory surgical centres (ASCS), and others. As per the report, the hospitals and pharmacies segment leads the market.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. As per the report, North America dominates the market. Some of the factors accelerating the North America diabetic retinopathy market include the increasing prevalence of diabetes, growing awareness about diabetic retinopathy, and advancements in diagnostic and treatment technologies.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global diabetic retinopathy market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Alimera Sciences, Allergan PLC, Ampio Pharmaceuticals, Bayer Healthcare, BCN Peptides, Genentech, Kowa Group, Novartis AG, Regeneron Pharmaceuticals Inc., Sirnaomics Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global diabetic retinopathy market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global diabetic retinopathy market?
  • What is the impact of each driver, restraint, and opportunity on the global diabetic retinopathy market?
  • What are the key regional markets?
  • Which countries represent the most attractive diabetic retinopathy market?
  • What is the breakup of the market based on the type?
  • Which is the most attractive type in the diabetic retinopathy market?
  • What is the breakup of the market based on the treatment type?
  • Which is the most attractive treatment type in the diabetic retinopathy market?
  • What is the breakup of the market based on the end-user?
  • Which is the most attractive end-user in the diabetic retinopathy market?
  • What is the competitive structure of the global diabetic retinopathy market?
  • Who are the key players/companies in the global diabetic retinopathy market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Diabetic Retinopathy Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Proliferative Diabetic Retinopathy
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Non-proliferative Retinopathy
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Treatment Type

  • 7.1 Anti VEGF Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Steroid Implants
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Laser Surgeries
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Vitrectomy
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End-User

  • 8.1 Hospitals and Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Eye Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Ambulatory Surgical Centres (ASCs)
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Alimera Sciences
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
    • 13.3.2 Allergan Plc
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Ampio Pharmaceuticals
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
    • 13.3.4 Bayer Healthcare
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 BCN Peptides
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
    • 13.3.6 Genentech
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 SWOT Analysis
    • 13.3.7 Kowa Group
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
    • 13.3.8 Novartis AG
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
    • 13.3.9 Regeneron Pharmaceuticals Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Sirnaomics Inc.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio

List of Figures

  • Figure 1: Global: Diabetic Retinopathy Market: Major Drivers and Challenges
  • Figure 2: Global: Diabetic Retinopathy Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Diabetic Retinopathy Market: Breakup by Type (in %), 2023
  • Figure 4: Global: Diabetic Retinopathy Market: Breakup by Treatment Type (in %), 2023
  • Figure 5: Global: Diabetic Retinopathy Market: Breakup by End-User (in %), 2023
  • Figure 6: Global: Diabetic Retinopathy Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Diabetic Retinopathy Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 8: Global: Diabetic Retinopathy (Proliferative Diabetic Retinopathy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Diabetic Retinopathy (Proliferative Diabetic Retinopathy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Diabetic Retinopathy (Non-proliferative Retinopathy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Diabetic Retinopathy (Non-proliferative Retinopathy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Diabetic Retinopathy (Anti VEGF Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Diabetic Retinopathy (Anti VEGF Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Diabetic Retinopathy (Steroid Implants) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Diabetic Retinopathy (Steroid Implants) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Diabetic Retinopathy (Laser Surgeries) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Diabetic Retinopathy (Laser Surgeries) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Diabetic Retinopathy (Vitrectomy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Diabetic Retinopathy (Vitrectomy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Diabetic Retinopathy (Hospitals and Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Diabetic Retinopathy (Hospitals and Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Diabetic Retinopathy (Eye Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Diabetic Retinopathy (Eye Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Diabetic Retinopathy (Ambulatory Surgical Centres-ASCs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Diabetic Retinopathy (Ambulatory Surgical Centres-ASCs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Diabetic Retinopathy (Others) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Diabetic Retinopathy (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: North America: Diabetic Retinopathy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: North America: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: United States: Diabetic Retinopathy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: United States: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Canada: Diabetic Retinopathy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Canada: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Asia Pacific: Diabetic Retinopathy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Asia Pacific: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: China: Diabetic Retinopathy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: China: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Japan: Diabetic Retinopathy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Japan: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: India: Diabetic Retinopathy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: India: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: South Korea: Diabetic Retinopathy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: South Korea: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Australia: Diabetic Retinopathy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Australia: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Indonesia: Diabetic Retinopathy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Indonesia: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Others: Diabetic Retinopathy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Others: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Diabetic Retinopathy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Germany: Diabetic Retinopathy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Germany: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: France: Diabetic Retinopathy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: France: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United Kingdom: Diabetic Retinopathy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United Kingdom: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Italy: Diabetic Retinopathy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Italy: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Spain: Diabetic Retinopathy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Spain: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Russia: Diabetic Retinopathy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Russia: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Diabetic Retinopathy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Latin America: Diabetic Retinopathy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Latin America: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Brazil: Diabetic Retinopathy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Brazil: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Mexico: Diabetic Retinopathy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Mexico: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Diabetic Retinopathy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Middle East and Africa: Diabetic Retinopathy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Middle East and Africa: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Global: Diabetic Retinopathy Industry: SWOT Analysis
  • Figure 77: Global: Diabetic Retinopathy Industry: Value Chain Analysis
  • Figure 78: Global: Diabetic Retinopathy Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Diabetic Retinopathy Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Diabetic Retinopathy Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Diabetic Retinopathy Market Forecast: Breakup by Treatment Type (in Million US$), 2024-2032
  • Table 4: Global: Diabetic Retinopathy Market Forecast: Breakup by End-User (in Million US$), 2024-2032
  • Table 5: Global: Diabetic Retinopathy Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Diabetic Retinopathy Market: Competitive Structure
  • Table 7: Global: Diabetic Retinopathy Market: Key Players